2017
DOI: 10.21470/1678-9741-2016-0007
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Introduction The mortality due to cardiogenic shock complicating acute myocardial infarction (AMI) is high even in patients with early revascularization. Infusion of low dose recombinant human brain natriuretic peptide (rhBNP) at the time of AMI is well tolerated and could improve cardiac function.Objective The objective of this study was to evaluate the hemodynamic effects of rhBNP in AMI patients revascularized by emergency percutaneous coronary intervention (PCI) who developed cardiogenic shock.Methods A to… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
16
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(16 citation statements)
references
References 34 publications
(39 reference statements)
0
16
0
Order By: Relevance
“…The study published by Xu et al 26 reported NT-proBNP levels 4 hours after treatment; however, another three studies 14,22,28 provided NT-proBNP levels more than 24 hours after treatment. The study by Xu et al 26 was a major source of heterogeneity across the four studies; therefore, the sensitivity analysis was performed after excluding their study.…”
Section: Sensitivity Analysismentioning
confidence: 99%
See 1 more Smart Citation
“…The study published by Xu et al 26 reported NT-proBNP levels 4 hours after treatment; however, another three studies 14,22,28 provided NT-proBNP levels more than 24 hours after treatment. The study by Xu et al 26 was a major source of heterogeneity across the four studies; therefore, the sensitivity analysis was performed after excluding their study.…”
Section: Sensitivity Analysismentioning
confidence: 99%
“…A total of 10 studies involving 870 participants were included in the meta-analysis. 14,[20][21][22][23][24][25][26][27][28] The study selection process is shown in Figure 1. Table 1 shows the basic characteristics of the 10 included studies.…”
Section: Literature Search and Study Selectionmentioning
confidence: 99%
“…Seven trials investigated mechanical circulatory assist devices such as an intra-aortic balloon pump, Tandem-Heart®(LivaNova, London, UK) and Impella® (Abiomed, Danvers, MA, USA) [16,[18][19][20][21][22], 8 trials investigated pharmacological treatments [15,17,[23][24][25][26][27][28], 3 investigated coronary interventions (PCI) [10,13,29], and 1 trial investigated targeted temperature management [16]. The trials were published from 1999 onwards.…”
Section: Study Characteristicsmentioning
confidence: 99%
“…A total of 12 (63%) trials required signs of impaired end-organ perfusion [10, 11, 15, 17, 19-23, 26, 30], with clinical assessment being a central part of which 10 trials required at least 1 of several possible symptoms; 11 trials (58%) included low urine output defined either as a urine output <30 ml/h or more unspecific as "oliguria" [10, 11, 13, 15, 19-23, 26, 30]. Altered mental status was used in 6 (32%) trials [11,13,22,23,26,30] and clinically assessed cold and/or clammy skin and limbs was used in 12 trials (63%) [10, 11, 13, 15, 17, 19-23, 26, 30]. Elevated arterial lactate as a biochemical sign of hypoperfusion was used as an inclusion criterion in 5 (26%) trials [11,13,22,23,30].…”
Section: Definition Of Cardiogenic Shockmentioning
confidence: 99%
See 1 more Smart Citation